Biomarker Reference · Anti-SLA/LP
Anti-Soluble Liver Antigen / Liver-Pancreas Antibodies (Anti-SLA/LP) is a clinical biomarker used in gastrointestinal assessment. Anti-SLA/LP antibodies recognise a cytosolic transfer-RNA-protein complex involved in selenocysteine incorporation. It is measured in 1 laboratory test on BiomarkersLabs.com.
Anti-SLA/LP antibodies recognise a cytosolic transfer-RNA-protein complex involved in selenocysteine incorporation. They are highly specific for autoimmune hepatitis and are not found in other autoimmune or viral liver diseases. The antibody is present in a minority of AIH patients but its presence is virtually diagnostic.
Anti-SLA/LP is detected in 10–30 per cent of patients with autoimmune hepatitis and is highly specific — a positive result strongly supports the diagnosis. Patients who are anti-SLA/LP positive often have more severe disease, a higher relapse rate after treatment withdrawal, and a greater need for long-term immunosuppression. The antibody can occur in isolation or alongside ANA and ASMA, and it is particularly useful in seronegative cases where other autoantibodies are absent.
Reference ranges vary by laboratory and assay platform. Interpret in context of the issuing laboratory's stated range.
1 test on BiomarkersLabs.com include this biomarker.
Related Biomarkers
Available exclusively to verified licensed healthcare practitioners. CLIA-certified laboratory results delivered to your secure portal.
Create Free Account